Predictive Biomarkers and Personalized Medicine Phase II Trial of MEK Inhibitor Selumetinib ( AZD 6244 , ARRY-142886 ) in Patients with BRAFV 600 E / K-Mutated Melanoma

@inproceedings{Catalanotti2013PredictiveBA,
  title={Predictive Biomarkers and Personalized Medicine Phase II Trial of MEK Inhibitor Selumetinib ( AZD 6244 , ARRY-142886 ) in Patients with BRAFV 600 E / K-Mutated Melanoma},
  author={Federica Catalanotti and David B. Solit and Melissa Pulitzer and Michael F. Berger and Sasinya N. Scott and Tunc Iyriboz and Mario E. Lacouture and Katherine S. Panageas and Jedd D Wolchok and Richard D. Carvajal and Gary K. Schwartz and Neal Rosen and Paul B Chapman},
  year={2013}
}
Purpose: Test the hypothesis that in BRAF-mutated melanomas, clinical responses to selumetinib, a MEK inhibitor, will be restricted to tumors in which the PI3K/AKT pathway is not activated. Experimental Design:We conducted a phase II trial in patients withmelanomawhose tumors harbored a BRAF mutation. Patients were stratified by phosphorylated-AKT (pAKT) expression (high vs. low) and treated with selumetinib 75 mg per os twice daily. Pretreatment tumors were also analyzed for genetic changes in… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastastic cutaneous melanoma harboring BRAFV600 or NRASmutations

PA Ascierto, C Berking, +3 authors P Queirolo
J Clin Oncol • 2012
View 1 Excerpt

PTEN immunohistochemical expression as part of the correlative analysis in theBRIM-2 trial

JA Sosman, AC Pavlick, +3 authors CL Cowey
JClinOncol • 2012

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2012
View 2 Excerpts

Similar Papers

Loading similar papers…